Fifth, we did a sensitivity analysis on renin-angiotensin system (RAS)-acting agents and found that the risk of AD in patients receiving angiotensin-converting enzyme inhibitors or direct renin inhibitors was not significantly different from those receiving angiotensin-receptor blockers. The gene discussed is ACE; the disease is Alzheimer disease.